|
| Values | |
| Mean age (years) | 27.9 ± 5.5 | |
| Mean duration of disease (years) | 15.0 ± 9.7 | |
| Mean SLEDAI | 12.1 ± 1.6 | |
| SLE clinical features |
| |
|
| Nephropathy | 17 (62.9%) |
|
| Pulmonary hypertension | 5 (18.5%) |
|
| Arthritis | 13 (48.1%) |
|
| Vasculitis | 11 (0.7%) |
| Corticosteroid therapy (current use) | 27 (100%) | |
| Other previously used immunosuppressive drugs |
| |
|
| Anti-malaria therapy | 23 (85.1%) |
|
| Mycophenolate mofetil | 12 (44.4%) |
|
| Methotrexate | 5 (18.5%) |
|
| Azathioprine | 0 (0%) |
|
| Cyclophosphamide (CTX) | 0 (0%) |